AGENDA

Basel, 15 - 17 October 2019

Schedule

Create your personal agenda –check the favourite icon

Oct 1509:00
Conference pass

Chair's opening remarks

Protein Engineering
Oct 1509:00
Conference pass

Chair's opening remarks

Armed Antibodies
Oct 1509:05
Conference pass

Antibody drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index

Protein Engineering
Oct 1509:05
Conference pass

Antibody drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index

Armed Antibodies
Oct 1509:55
Conference pass

Reserved for supporting partner

Protein Engineering
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 (0)207 092 1297
Oct 1509:55
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 (0)207 092 1297
Oct 1511:20
Conference pass

Plenary roundtable session

Protein Engineering
TABLE 1 Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, and Fc fusion proteins
TABLE 2 Title TBA
TABLE 3 Therapeutic antibodies-line of sight
TABLE 4 Establishing early development strategies for therapeutic proteins
TABLE 5 Reserved for BioIVT
TABLE 6 Multispecific antibodies: challenges & analytical strategies
Oct 1511:20
Conference pass

Plenary roundtable session

Armed Antibodies
TABLE 1 Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, and Fc fusion proteins
TABLE 2 Title TBA
TABLE 3 Therapeutic antibodies-line of sight
TABLE 4 Establishing early development strategies for therapeutic proteins
TABLE 5 Reserved for BioIVT
TABLE 6 Multispecific antibodies: challenges & analytical strategies
Oct 1514:10
Conference pass

Modulating therapeutic window of antibody drug conjugates by protein engineering

Protein Engineering
  • Engineering multiple properties of monoclonal antibodies to maximize the therapeutic window
  • Properties such as conjugation location, antibody internalization, antibody affinity, drug and linker type, as well as use of dual payloads will be discussed
Oct 1514:10
Conference pass

New payloads for antibody-drug conjugates

Armed Antibodies
  • Exploring drugs with novel mechanisms of action and learning the requirements for effective ADC payloads
  • Impact of drug load on ADC activity
  • The importance of payload metabolism and how to avoid using antibody or small molecule engineering
Oct 1514:30
Conference pass

Developability: Evaluating specificity, immunogenicity, functionality & manufacturability for lead candidate selection

Protein Engineering
  • Understand the latest series of in silico computational models, analytics, in vitro and ex vivo experiments used in developability assessment.
  • Characterise a molecules Specificity, Immunogenicity, Safety, Functionality and Manufacturability.
  • Data generated informs sequence, structural, formulation and process refinements to select the best candidate for manufacture.
Oct 1514:30
Conference pass

Amunix XTEN® polypeptides and THIOMAB™ antibodies to enable site-specific high-DAR ADCs with acceptable pharmacokinetics and efficacy

Armed Antibodies
  • Conjugation and analytics development for high-DAR THIOMAB™ antibody-XTEN®-drug conjugates (TXCs)
  • In vitro and in vivo validation of TXC platform
  • Application toward delivery of novel payloads
Oct 1514:50
Conference pass

Protein and antibody engineering using yeast surface display

Protein Engineering
  • Isolation of antibodies with prescribed properties by combining animal immunization and yeast surface display
  • Protein engineering and affinity optimization
  • Insights into the library construction process
Oct 1514:50
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 (0)207 092 1297
Oct 1515:10
Conference pass

Advancing therapeutic protein development using a novel O-glycan-based conjugation approach

Protein Engineering
  • Innovative technology utilising a novel peptide-based tag to generate site-specific, homogeneously-labelled recombinant secretory proteins containing modified O-glycans.
  • Robust incorporation of functionalised O-glycans to recombinant proteins using a UDP-galactose-4-eperimase KO, serum-free, expression system.
  • Externally supplied sugars such as N-acetylgalactosamine (GalNac) or N-azidoacetylgalactosamine (GalNAz), can be utilised to generate site-specific O-glycosylation on demand, e.g. for Click chemistry applications.
  • The technology represents an elegant, controllable approach to generate bespoke, consistently labelled recombinant proteins.
Oct 1515:10
Conference pass

Application of anti-glycan antibodies against cancer

Armed Antibodies
  • Antibody discovery and development against glycosylated targets on cancer cells
  • Characterisation and validation of glycol epitopes
  • Evaluation of antibodies as ADCCs, ADCs, CAR-Ts and Bispecific Antibodies
Oct 1516:30
Conference pass

Harnessing antibody light chains to generate multispecific native antibody formats

Protein Engineering
  • The 3 light chain CDRs are sufficient to drive high affinity and specific binding
  • Combinatorial pairing of different light chains with a single heavy chain generates bi- and multispecific antibody formats
  • These formats fully retain the native structure of a human IgG
  • Different applications of this approach will be presented
Oct 1516:30
Conference pass

Title TBA

Armed Antibodies
Oct 1516:50
Conference pass

Design and validation of Alexandria™, Isogenica’s fully synthetic human antibody library

Protein Engineering
  • Alexandria™ is Isogenica’s fully synthetic, developability optimized human antibody library
  • Alexandria™ offers unrivalled diversity, due to inclusion of many heavy and kappa light chain germlines and use of fully synthetic CDR1, -2 and -3 cassettes across the whole repertoire.
  • As such, it avoids the issues of immunodominant epitopes, self-antigen tolerance and skewed diversity intrinsic to immunization based approaches or naïve and semi-synthetic libraries
  • We will present validation data on use of the library to generate binders to various target classes
Oct 1517:10
Conference pass

Title TBA

Protein Engineering
Oct 1517:10
Conference pass

Reserved for supporting partner

Armed Antibodies
If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 (0)207 092 1297
Oct 1517:30
Conference pass

Creating multifunctional biologics for immuno-oncology using Humabody VH from the Crescendo Mouse

Protein Engineering
  • Crescendo’s proprietary transgenic mouse generates highly diverse fully human VH domain (‘Humabody’) building blocks
  • Humabody VH can be combined in various formats which lack the constraints of traditional mAbs, enabling multifunctional molecules to be constructed which deliver enhanced therapeutic benefit
  • Examples of differentiated biology will focus on applications in immuno-oncology
Oct 1517:50
Conference pass

Antibody affinity regulated by a universal switch module

Protein Engineering
  • Fusing calmodulin as a linker into a scFv-fragment to gain a M13 peptide and Ca dependent change in affinity
  • MST measurement in "on" and "off" mode with cyclic permutation variations of the calmodulin module
  • Comparison of different antibodies using the optimized calmodulin module
Oct 1517:50
Conference pass

Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Armed Antibodies
  • Introducing a novel ADC-linker technology enabling site-specific payload conjugation to native antibodies (i.e. no need to reduce or re-engineer the antibody)
  • Biophysical characterization of generated ADCs will be shown
  • ADC in-vitro and in-vivo performance in comparison to other conjugation technologies will be shown
last published: 09/May/19 09:15 GMT

 




It was a great, no-extra-cost opportunity to learn about technological advances in the field of immunology.


Tomasz Dobrzycki, Scientist, Immunocore Ltd



 

 

 

There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.